We recently upgraded Dabur to BUY rating on likely faster recovery in rural economy (where Dabur has an edge over competition) on multiple tailwinds, and Dabur realigning its supply chain with ayurvedic portfolio to boot. We estimate consolidated sales and EPS CAGR of 9% and 13% over FY17-20E.